Compounds for treatment of heart failure
US9566342B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2011 |
| Grant date | Feb 14, 2017 |
| Priority date | — |
| Expiry date | Apr 5, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C237/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.